Dissertation
Dissertation > Medicine, health > Oncology > Respiratory system tumors > Lung tumors

The Molecular Biology of Rh-endostatin Plus Chemotherapy as Adjuvant Treatment for Non-small Lung Cancer

Author YangXiaoYu
Tutor ZhouTao
School Dalian Medical University
Course Oncology
Keywords Non-small cell lung cancer VEGF BRCA1 ERCC1 β- tubulin CD3 Immunohistochemistry Endostar ( recombinant human endostatin )
CLC R734.2
Type Master's thesis
Year 2011
Downloads 35
Quotes 0
Download Dissertation

Objective: Non-small cell lung cancer (NSCLC) accounts for about 80% of lung cancer, surgical resection is an important treatment for NSCLC after complete resection of the 5-year survival rates were: IA of 67%, IB of 57%, IIA period 55%, IIB of 39%, IIIA of 32%. Non-small cell lung cancer after standard therapy in addition to Phase I of the cases, the required postoperative adjuvant chemotherapy to improve survival, but there is still a high rate of recurrence and mortality. With the development of molecular biology in recent years, adjuvant targeted therapy more and more attention, including adjuvant chemotherapy combined Endostar targeted therapy to enter non-small cell lung cancer adjuvant therapy area, and is currently underway to find a suitable postoperative adjuvant chemotherapy combined targeted therapy Endostar best adapt to the crowd, in order to exert maximum efficacy and Endostar better use of health resources, improve the survival rate and reduce the recurrence rate of positive clinical significance. The expression of some genes in NSCLC treatment efficacy impact on people's attention. The level of molecular biology experiments trying to find NP (vinorelbine cisplatin) chemotherapy and Endostar biomarkers predicting the outcome, such as VEGF (vascular endouthelial growth factor, vascular endothelial growth factor), BRCA1, ERCC1, β-micro tubulin, CD3 expression for postoperative chemotherapy and targeted therapy Endostar provide clinical reference. Methods: 36 patients met the study criteria non-small cell lung cancer patients were divided into two groups namely endostar chemotherapy group and the chemotherapy group, made its pathological paraffin blocks 6μm thick slices, using immunohistochemical method to detect VEGF, BRCA1, ERCC1, β-tubulin, CD3 expression. Adjuvant chemotherapy combined Endostar targeted therapy four cycles, 21-day cycle. Chemotherapy is NP program. Statistics before the end of the study enrolled patients with disease-free survival (DFS), combined with the pre-treatment of the molecular biology test results, statistical correlation. Results: In this study, 36 patients, NP endostar group, the median DFS than a simple NP chemotherapy group was significantly longer (18 months vs14 months), P = 0.001, P lt; 0.05. 2. Present study 36 patients VEGF expression is: NP endostar low expression group (- ~) 6 cases with high expression (~) 12 cases; NP chemotherapy alone group with low expression (- ~) 6 cases with high expression (~) in 12 cases. The statistical analysis showed that: VEGF low expression, NP endostar Median DFS compared with chemotherapy alone group (19 months vs12 months) has risen markedly, P = 0.042, P lt; 0.05; VEGF overexpression, NP endostar group The median DFS compared with chemotherapy alone significantly increased (18 months vs14 months), P = 0.022, P lt; 0.05. 3. present study 36 patients BRCA1 expression is: NP endostar group with low expression (- ~) 4 cases with high expression (~) 14 cases; NP chemotherapy alone group with low expression (- ~) 4 cases, high expression (~) in 14 cases. The statistical analysis showed that: BRCA1 low expression, NP endostar Median DFS compared with chemotherapy alone group had significantly improved (15 months vs8 months), P = 0.014, P lt; 0.05; BRCA1 overexpression, NP endostar group The median DFS compared with chemotherapy alone significantly increased (18 months vs17 months), P = 0.007, P lt; 0.05. 4. present study 36 patients ERCC1 expression is: NP endostar group with low expression (- ~) 7 cases with high expression (~) 11 cases; NP chemotherapy alone group with low expression (- ~) 5 cases with high expression (~) in 13 cases. The statistical analysis showed that: ERCC1 low expression, NP endostar Median DFS compared with chemotherapy alone group had no significant difference (15 months vs14 months), P gt; 0.05 (P = 0.31); ERCC1 high expression, NP Endostar The median DFS compared with chemotherapy alone group (19 months vs13 months) has risen markedly, P lt; 0.05 (P = 0.001). 5 In this study, 36 patients β-tubulin expression is: NP endostar low expression group (- ~) in 8 cases, high expression (~) 10 cases; NP chemotherapy alone group with low expression (- ~) 8 cases high expression (~) in 10 cases. The statistical analysis showed that: β-tubulin low expression, NP endostar Median DFS compared with chemotherapy alone group had no significant difference (18 months vs14 months), P = 0.209, P gt; 0.05; β-tubulin protein overexpression, NP endostar Median DFS compared with chemotherapy alone significantly increased (19 months vs12 months), P = 0.001, P lt; 0.05. 6. present study 36 patients CD3 expression is: NP En degree low expression group (- ~), 18 cases; NP chemotherapy alone group with low expression (- ~) in 18 patients. The statistical analysis showed that: CD3 low expression, NP endostar Median DFS compared with chemotherapy alone group was significantly longer (18 months vs14 months), P = 0.001, P lt; 0.05. Conclusions: 1 NSCLC adjuvant therapy, NP endostar group than the chemotherapy group, NP endostar Median DFS compared with NP chemotherapy alone group was significantly extended. 2 VEGF, BRCA1 high expression and low expression, NP Endostar compared with chemotherapy alone in patients with DFS were increased, with statistical significance; ERCC1 high expression, NP endostar Median DFS compared with chemotherapy alone group had significantly improved, there statistical significance; β-tubulin is highly expressed chemotherapy endostar Median DFS extended, with statistical significance; CD3 low expression, NP endostar group than the chemotherapy group, the median DFS was significantly prolonged, statistically significance. 3 based on high expression of VEGF and BRCA1, low expression; ERCC1, β-tubulin expression and high CD3 expression may be low on postoperative NSCLC treatment options endostar auxiliary NP has guiding significance.

Related Dissertations
More Dissertations